Page 167 - TD-3-4

Tumor Discovery CK2 deregulation in non-small-cell lung cancer

doi: 10.1126/scisignal.2004088 28. Filhol O, Giacosa S, Wallez Y, Cochet C. Protein kinase
CK in breast cancer: The CK2β regulatory subunit
16. Martínez-Jiménez F, Muiños F, Sentís I, et al. A compendium takes center stage in epithelial plasticity. Cell Mol Life Sci.
2
of mutational cancer driver genes. Nat Rev Cancer. 2015;72(17):3305-3322.
2020;20(10):555-572.
doi: 10.1007/s00018-015-1929-8
doi: 10.1038/s41568-020-0290-x
29. Litchfield DW, Bosc DG, Canton DA, Saulnier RB, Vilk G,
17. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: Zhang C. Functional specialization of CK isoforms and
A precision oncology knowledge base. JCO Precis Oncol. characterization of isoform-specific binding partners. Mol
2
2017;1:1-16.
Cell Biochem. 2001;227(12):21-29.
doi: 10.1200/PO.17.00011
30. Zonta F, Borgo C, Quezada Meza CP, et al. Contribution
18. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. of the CK catalytic isoforms α and α’ to the glycolytic
2
UALCAN: A portal for facilitating tumor subgroup gene phenotype of tumor cells. Cells. 2021;10(1):181.
expression and survival analyses. Neoplasia. 2017;19(8): doi: 10.3390/cells10010181
649-658.
31. Ackermann K, Neidhart T, Gerber J, Waxmann A, Pyerin W.
doi: 10.1016/j.neo.2017.05.002 The catalytic subunit alpha’ gene of human protein kinase
19. Cai L, Lin S, Girard L, et al. LCE: An open web portal to CK (CSNK A ): Genomic organization, promoter
2
2
2
explore gene expression and clinical associations in lung identification and determination of Ets1 as a key regulator.
cancer. Oncogene. 2019;38(14):2551-2564. Mol Cell Biochem. 2005;274(1-2):91-101.
doi: 10.1038/s41388-018-0588-2 doi: 10.1007/s11010-005-3076-2
20. Bartha Á, Győrffy B. TNMplot.Com: A web tool for the 32. Sheida F, Razi S, Keshavarz-Fathi M, Rezaei N. The role
comparison of gene expression in normal, tumor and of myeloid-derived suppressor cells in lung cancer and
metastatic tissues. Int J Mol Sci. 2021;22(5):2622. targeted immunotherapies. Expert Rev Anticancer Ther.
2022;22(1):65-81.
doi: 10.3390/ijms22052622
doi: 10.1080/14737140.2022.2011224
21. Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of
tumor-infiltrating immune cells. Nucleic Acids Res. 33. Chen C, Hou J, Yu S, et al. Role of cancer-associated
2020;48(W1):W509-W514. fibroblasts in the resistance to antitumor therapy, and their
potential therapeutic mechanisms in non-small cell lung
doi: 10.1093/nar/gkaa407 cancer. Oncol Lett. 2021;21(5):413.
22. TCGA Research Network. Available from: https://www. doi: 10.3892/ol.2021.12674
cancer.gov/tcga [Last accessed on 2024 Nov 27].
34. Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-
23. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes associated fibroblasts and targeted therapy for cancer. Signal
Consortium. Pan-cancer analysis of whole genomes. Nature. Transduct Target Ther. 2021;6(1):218.
2020;578(7793):82-93.
doi: 10.1038/s41392-021-00641-0
doi: 10.1038/s41586-020-1969-6
35. Glabman RA, Choyke PL, Sato N. Cancer-associated
24. Firnau MB, Brieger A. CK and the hallmarks of cancer. fibroblasts: Tumorigenicity and targeting for cancer therapy.
2
Biomedicines. 2022;10(8):1987. Cancers (Basel). 2022;14(16):3906.
doi: 10.3390/biomedicines10081987 doi: 10.3390/cancers14163906
25. Chua MMJ, Ortega CE, Sheikh A, et al. CK in cancer: 36. Umansky V, Blattner C, Gebhardt C, Utikal J. The role
2
Cellular and biochemical mechanisms and potential of myeloid-derived suppressor cells (MDSC) in cancer
therapeutic target. Pharmaceuticals (Basel). 2017;10(1):18. progression. Vaccines (Basel). 2016;4(4):36.
doi: 10.3390/ph10010018 doi: 10.3390/vaccines4040036
26. Ortega CE, Seidner Y, Dominguez I. Mining CK in cancer. 37. Daya-Makin M, Sanghera JS, Mogentale TL, et al.
2
PLoS One. 2014;9(12):e115609. Activation of a tumor-associated protein kinase (P40TAK)
and casein kinase 2 in human squamous cell carcinomas
doi: 10.1371/journal.pone.0115609
and adenocarcinomas of the lung. Cancer Res. 1994;54(8):
27. Chua MMJ, Lee M, Dominguez I. Cancer-type 2262-2268.
dependent expression of CK transcripts. PLoS One. 38. Yaylim I, Isbir T. Enhanced casein kinase II (CK II) activity
2
2017;12(12):e0188854.
in human lung tumours. Anticancer Res. 2002;22(1A):
doi: 10.1371/journal.pone.0188854 215-218.

Volume 3 Issue 4 (2024) 13 doi: 10.36922/td.4571